| Year |
Citation |
Score |
| 2023 |
Chervoneva I, Peck AR, Sun Y, Yi M, Udhane SS, Langenheim JF, Girondo MA, Jorns JM, Chaudhary LN, Kamaraju S, Bergom C, Flister MJ, Hooke JA, Kovatich AJ, Shriver CD, ... ... Hyslop T, et al. High PD-L2 Predicts Early Recurrence of ER-Positive Breast Cancer. Jco Precision Oncology. 7: e2100498. PMID 36652667 DOI: 10.1200/PO.21.00498 |
0.51 |
|
| 2020 |
Tamirisa NP, Ren Y, Campbell BM, Thomas SM, Fayanju OM, Plichta JK, Rosenberger LH, Force J, Hyslop T, Hwang ES, Greenup RA. Treatment Patterns and Outcomes of Women with Breast Cancer and Supraclavicular Nodal Metastases. Annals of Surgical Oncology. PMID 32946012 DOI: 10.1245/S10434-020-09024-1 |
0.406 |
|
| 2020 |
Shah A, Polascik TJ, George DJ, Anderson J, Hyslop T, Ellis AM, Armstrong AJ, Ferrandino M, Preminger GM, Gupta RT, Lee WR, Barrett NJ, Ragsdale J, Mills C, Check DK, et al. Implementation and Impact of a Risk-Stratified Prostate Cancer Screening Algorithm as a Clinical Decision Support Tool in a Primary Care Network. Journal of General Internal Medicine. PMID 32875501 DOI: 10.1007/S11606-020-06124-2 |
0.302 |
|
| 2020 |
Magbanua MJM, Hendrix LH, Hyslop T, Barry WT, Winer EP, Hudis C, Toppmeyer D, Carey LA, Partridge AH, Pierga JY, Fehm T, Vidal-Martínez J, Mavroudis D, Garcia-Saenz JA, Stebbing J, et al. Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy. Journal of the National Cancer Institute. PMID 32770247 DOI: 10.1093/Jnci/Djaa113 |
0.389 |
|
| 2020 |
Crosby EJ, Acharya CR, Haddad AF, Rabiola CA, Lei G, Wei JP, Yang XY, Wang T, Liu CX, Wagner KU, Muller WJ, Chodosh LA, Broadwater G, Hyslop T, Shepherd JH, et al. Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32732224 DOI: 10.1158/1078-0432.Ccr-20-0389 |
0.334 |
|
| 2020 |
Plichta JK, Thomas SM, Sergesketter AR, Greenup RA, Rosenberger LH, Fayanju OM, Kimmick G, Force J, Hyslop T, Hwang ES. A Novel Staging System for De Novo Metastatic Breast Cancer Refines Prognostic Estimates. Annals of Surgery. PMID 32657941 DOI: 10.1097/Sla.0000000000004231 |
0.385 |
|
| 2020 |
Ong CT, Ren Y, Thomas SM, Stashko I, Hyslop T, Kimmick G, Blitzblau RC, Hwang ES, Grimm LJ, Greenup RA. Overall health at diagnosis predicts the risk of complications within the first year after breast cancer diagnosis. Breast Cancer Research and Treatment. PMID 32468334 DOI: 10.1007/S10549-020-05700-8 |
0.365 |
|
| 2020 |
Mundy LR, Rosenberger LH, Rushing CN, Atisha D, Pusic AL, Hollenbeck ST, Hyslop T, Hwang ES. The Evolution of Breast Satisfaction and Well-Being after Breast Cancer: A Propensity-Matched Comparison to the Norm. Plastic and Reconstructive Surgery. 145: 595-604. PMID 32097289 DOI: 10.1097/Prs.0000000000006535 |
0.362 |
|
| 2020 |
Satpathy S, Jaehnig EJ, Krug K, Kim BJ, Saltzman AB, Chan DW, Holloway KR, Anurag M, Huang C, Singh P, Gao A, Namai N, Dou Y, Wen B, Vasaikar SV, ... ... Hyslop T, et al. Microscaled proteogenomic methods for precision oncology. Nature Communications. 11: 532. PMID 31988290 DOI: 10.1038/S41467-020-14381-2 |
0.366 |
|
| 2020 |
Plichta JK, Thomas SM, Vernon R, Fayanju OM, Rosenberger LH, Hyslop T, Hwang ES, Greenup RA. Breast cancer tumor histopathology, stage at presentation, and treatment in the extremes of age. Breast Cancer Research and Treatment. PMID 31980967 DOI: 10.1007/S10549-020-05542-4 |
0.377 |
|
| 2020 |
Fayanju OM, Ren Y, Greenup RA, Plichta JK, Rosenberger LH, Force J, Suneja G, Devi GR, King TA, Nakhlis F, Hyslop T, Hwang ES. Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients. Breast Cancer Research and Treatment. PMID 31960171 DOI: 10.1007/S10549-020-05529-1 |
0.365 |
|
| 2020 |
Plichta JK, Rushing CN, Lewis HC, Blazer DG, Hyslop T, Greenup RA. Missing data in breast cancer: Relationship with survival in national databases. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E19114 |
0.376 |
|
| 2020 |
Ryser MD, Hendrix L, Thomas SM, Lynch T, McCarthy A, Mohammed Z, Francescatti AB, Frank ES, Partridge AH, Thompson AM, Hyslop T, Hwang ES. Ipsilateral invasive cancer risk after diagnosis with ductal carcinoma in situ (DCIS): Comparison of patients with and without index surgery. Journal of Clinical Oncology. 38: 519-519. DOI: 10.1200/Jco.2020.38.15_Suppl.519 |
0.322 |
|
| 2020 |
Herold K, Yee LD, Kalu CM, Kruper LL, Jones VC, Polverini AC, Clancy S, Chavez TA, Alva-Ornelas JA, Chavez NR, Rippberger EJ, Tomsic J, Sistrunk C, Idassi O, Schmolze DB, ... ... Hyslop T, et al. Abstract B109: Architecture of increased breast cancer risk Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp18-B109 |
0.35 |
|
| 2020 |
Chavez TA, Thai C, Sanchez A, Kruper LL, Jones VC, Clancy S, Polverini AC, Yee LD, Vito CA, Chávez NR, Nuñez A, Rippberger EJ, Wong AK, Herold K, Kalu CMK, ... ... Hyslop T, et al. Abstract A083: Diversifying breast cancer clinical trial accrual: An approach to recruitment at a Comprehensive Cancer Center Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp18-A083 |
0.368 |
|
| 2020 |
Chavez NR, Nunez A, Wong AK, Chavez TA, Rippberger E, Thai C, Sanchez A, Idassi OM, Round KM, Kennedy K, Robles M, Alva-Ornelas JA, Tomsic J, Kalu CMK, Kruper LL, ... ... Hyslop T, et al. Abstract A082: Influencing women's attitudes toward participation in breast cancer clinical research: Improving inclusion of women of color Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp18-A082 |
0.301 |
|
| 2020 |
Hoadley KA, Powell BC, Kanavy D, Marron D, Mose LE, Hyslop T, Berry DA, Hahn O, Tolaney SM, Sikov WM, Perou CM, Carey LA. Abstract P4-05-03: Mutational analysis of triple-negative breast cancer (TNBC): CALGB 40603 (Alliance) Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P4-05-03 |
0.322 |
|
| 2020 |
Sammons S, Ren Y, Force J, Fayanju OM, Rosenberger LH, Plichta JK, Kimmick G, Westbrook K, Dent S, Anders C, Thomas SM, Hyslop T, Hwang ES, Marcom PK, Greenup RA. Abstract P3-08-10: Characterization of oncotype DX recurrence score and chemotherapy utilization patterns in young women (≤40) with early stage ER+/HER-, lymph node negative breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P3-08-10 |
0.387 |
|
| 2020 |
Rosenberg SM, Hendrix LH, Schreiber KL, Thompson AM, Bedrosian I, Hughes KS, Lynch T, Basila D, Collyar DE, Frank ES, Darai S, Lanahan C, Marks JR, Plichta JK, Hyslop T, et al. Abstract P1-21-07: The Patient-reported Outcomes after Routine Treatment of Atypical Lesions (PORTAL) study: Pain, psychosocial wellbeing, and quality of life among women undergoing guideline concordant care for DCIS vs. active surveillance for in situ and atypical lesions Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P1-21-07 |
0.312 |
|
| 2020 |
Satpathy S, Jaehnig E, Karsten K, Kim B, Saltzman A, Chan D, Holloway K, Anurag M, Huang C, Singh P, Gao A, Namai N, Dou Y, Wen B, Vasaikar S, ... ... Hyslop T, et al. Abstract GS2-05: Microscaled proteogenomic methods for precision oncology Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Gs2-05 |
0.408 |
|
| 2019 |
Musselwhite LW, Redding TS, Sims KJ, O'Leary MC, Hauser ER, Hyslop T, Gellad ZF, Sullivan BA, Lieberman D, Provenzale D. Advanced neoplasia in Veterans at screening colonoscopy using the National Cancer Institute Risk Assessment Tool. Bmc Cancer. 19: 1097. PMID 31718588 DOI: 10.1186/S12885-019-6204-1 |
0.326 |
|
| 2019 |
Mremi A, Broadwater G, Jackson K, Amsi P, Mbulwa C, Hyslop T, Ong C, Hall A. Breast cancer in Tanzanian, black American, and white American women: An assessment of prognostic and predictive features, including tumor infiltrating lymphocytes. Plos One. 14: e0224760. PMID 31703083 DOI: 10.1371/Journal.Pone.0224760 |
0.351 |
|
| 2019 |
Fayanju OM, Ren Y, Suneja G, Thomas SM, Greenup RA, Plichta JK, Rosenberger LH, Force J, Hyslop T, Hwang ES. Nodal Response to Neoadjuvant Chemotherapy Predicts Receipt of Radiation Therapy after Breast Cancer Diagnosis. International Journal of Radiation Oncology, Biology, Physics. PMID 31678225 DOI: 10.1016/J.Ijrobp.2019.10.039 |
0.388 |
|
| 2019 |
Cocce KJ, Jasper JS, Desautels TK, Everett L, Wardell S, Westerling T, Baldi R, Wright TM, Tavares K, Yllanes A, Bae Y, Blitzer JT, Logsdon C, Rakiec DP, Ruddy DA, ... ... Hyslop T, et al. The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer. Cell Reports. 29: 889-903.e10. PMID 31644911 DOI: 10.1016/J.Celrep.2019.09.032 |
0.336 |
|
| 2019 |
Greenup RA, Rushing C, Fish L, Campbell BM, Tolnitch L, Hyslop T, Peppercorn J, Wheeler SB, Zafar SY, Myers ER, Hwang ES. Financial Costs and Burden Related to Decisions for Breast Cancer Surgery. Journal of Oncology Practice. JOP1800796. PMID 31356147 DOI: 10.1200/Jop.18.00796 |
0.34 |
|
| 2019 |
Plichta JK, Thomas SM, Sergesketter AR, Greenup RA, Fayanju OM, Rosenberger LH, Tamirisa N, Hyslop T, Hwang ES. Clinical and pathological stage discordance among 433,514 breast cancer patients. American Journal of Surgery. PMID 31350005 DOI: 10.1016/J.Amjsurg.2019.07.016 |
0.359 |
|
| 2019 |
Greenup RA, Rushing CN, Fish LJ, Lane WO, Peppercorn JM, Bellavance E, Tolnitch L, Hyslop T, Myers ER, Zafar SY, Hwang ES. Perspectives on the Costs of Cancer Care: A Survey of the American Society of Breast Surgeons. Annals of Surgical Oncology. PMID 31342390 DOI: 10.1245/S10434-019-07594-3 |
0.362 |
|
| 2019 |
Zambeli-Ljepović A, Wang F, Dinan MA, Hyslop T, Stang MT, Roman SA, Sosa JA, Scheri RP. Extent of surgery for low-risk thyroid cancer in the elderly: Equipoise in survival but not in short-term outcomes. Surgery. PMID 31288935 DOI: 10.1016/J.Surg.2019.05.035 |
0.328 |
|
| 2019 |
Martín M, Loibl S, Hyslop T, De la Haba-Rodríguez J, Aktas B, Cirrincione CT, Mehta K, Barry WT, Morales S, Carey LA, Garcia-Saenz JA, Partridge A, Martinez-Jañez N, Hahn O, Winer E, et al. Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. European Journal of Cancer (Oxford, England : 1990). 117: 91-98. PMID 31276981 DOI: 10.1016/J.Ejca.2019.06.002 |
0.359 |
|
| 2019 |
Zambeli-Ljepović A, Wang F, Dinan MA, Hyslop T, Roman SA, Sosa JA, Scheri RP. Low-Risk Thyroid Cancer in Elderly: Total Thyroidectomy/RAI Predominates but Lacks Survival Advantage. The Journal of Surgical Research. 243: 189-197. PMID 31185435 DOI: 10.1016/J.Jss.2019.05.029 |
0.334 |
|
| 2019 |
Grimm LJ, Miller MM, Thomas SM, Liu Y, Lo JY, Hwang ES, Hyslop T, Ryser MD. Growth Dynamics of Mammographic Calcifications: Differentiating Ductal Carcinoma in Situ from Benign Breast Disease. Radiology. 182599. PMID 31112087 DOI: 10.1148/Radiol.2019182599 |
0.333 |
|
| 2019 |
Sergesketter AR, Thomas SM, Fayanju OM, Menendez CS, Rosenberger LH, Greenup RA, Hyslop T, Parrilla Castellar ER, Hwang ES, Plichta JK. The Influence of Age on the Histopathology and Prognosis of Atypical Breast Lesions. The Journal of Surgical Research. 241: 188-198. PMID 31028940 DOI: 10.1016/J.Jss.2019.03.047 |
0.359 |
|
| 2019 |
Snook AE, Baybutt TR, Xiang B, Abraham TS, Flickinger JC, Hyslop T, Zhan T, Kraft WK, Sato T, Waldman SA. Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. Journal For Immunotherapy of Cancer. 7: 104. PMID 31010434 DOI: 10.1186/S40425-019-0576-2 |
0.537 |
|
| 2019 |
Hwang ES, Hyslop T, Lynch T, Frank E, Pinto D, Basila D, Collyar D, Bennett A, Kaplan C, Rosenberg S, Thompson A, Weiss A, Partridge A. The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). Bmj Open. 9: e026797. PMID 30862637 DOI: 10.1136/Bmjopen-2018-026797 |
0.358 |
|
| 2019 |
Ryser MD, Weaver DL, Zhao F, Worni M, Grimm LJ, Gulati R, Etzioni R, Hyslop T, Lee SJ, Hwang ES. Cancer Outcomes in DCIS Patients Without Locoregional Treatment. Journal of the National Cancer Institute. PMID 30759222 DOI: 10.1093/Jnci/Djy220 |
0.34 |
|
| 2019 |
Turner MC, Keenan JE, Rushing CN, Gulack BC, Nussbaum DP, Benrashid E, Hyslop T, Strickler JH, Mantyh CR, Migaly J. Adjuvant Chemotherapy Improves Survival Following Resection of Locally Advanced Rectal Cancer with Pathologic Complete Response. Journal of Gastrointestinal Surgery : Official Journal of the Society For Surgery of the Alimentary Tract. PMID 30635829 DOI: 10.1007/S11605-018-04079-8 |
0.343 |
|
| 2019 |
Crosby EJ, Gwin WR, Blackwell K, Marcom PK, Chang S, Maecker HT, Broadwater G, Hyslop TM, Kim S, Rogatko A, Lubkov V, Snyder JC, Osada T, Hobeika A, Morse MA, et al. Vaccine-induced memory CD8+ T cells provide clinical benefit in HER2 expressing breast cancer: a mouse to human translational study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30635338 DOI: 10.1158/1078-0432.Ccr-18-3102 |
0.337 |
|
| 2019 |
Crosby E, Gwin W, Chang S, Maecker H, Lubkov V, Snyder J, Broadwater G, Hyslop T, Osada T, Hobeika A, Hartman Z, Morse M, Lyerly H. Abstract P2-09-16: CD8 T cells induced by novel alphaviral vector predict improved progression free survival in advanced HER2+ breast cancer patients Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P2-09-16 |
0.356 |
|
| 2018 |
Plichta JK, Ren Y, Thomas SM, Greenup RA, Fayanju OM, Rosenberger LH, Hyslop T, Hwang ES. Implications for Breast Cancer Restaging Based on the 8th Edition AJCC Staging Manual. Annals of Surgery. PMID 30312199 DOI: 10.1097/Sla.0000000000003071 |
0.379 |
|
| 2018 |
Butt J, Varga MG, Blot WJ, Teras L, Visvanathan K, Le Marchand L, Haiman C, Chen Y, Bao Y, Sesso HD, Wassertheil-Smoller S, Ho GYF, Tinker LE, Peek RM, Potter JD, ... ... Hyslop T, et al. Serological response to Helicobacter pylori proteins associate with risk of colorectal cancer among diverse populations in the United States. Gastroenterology. PMID 30296434 DOI: 10.1053/J.Gastro.2018.09.054 |
0.311 |
|
| 2018 |
Tran TH, Utama FE, Sato T, Peck AR, Langenheim JF, Udhane SS, Sun Y, Liu C, Girondo MA, Kovatich AJ, Hooke JA, Shriver CD, Hu H, Palazzo J, Bibbo M, ... ... Hyslop TM, et al. Loss of nuclear localized Parathyroid Hormone-related Protein in primary breast cancer predicts poor clinical outcome and correlates with suppressed Stat5 signaling. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30097435 DOI: 10.1158/1078-0432.Ccr-17-3280 |
0.62 |
|
| 2018 |
Fayanju OM, Ren Y, Thomas SM, Greenup RA, Plichta JK, Rosenberger LH, Tamirisa N, Force J, Boughey JC, Hyslop T, Hwang ES. The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB). Annals of Surgery. PMID 30048319 DOI: 10.1097/Sla.0000000000002953 |
0.41 |
|
| 2018 |
Park TS, Thomas SM, Rosenberger LH, Fayanju OM, Plichta JK, Blitzblau RC, Ong CT, Hyslop T, Hwang ES, Greenup RA. The Association of Extent of Axillary Surgery and Survival in Women with N2-3 Invasive Breast Cancer. Annals of Surgical Oncology. PMID 29978365 DOI: 10.1245/S10434-018-6587-2 |
0.364 |
|
| 2018 |
Tamirisa N, Thomas SM, Fayanju OM, Greenup RA, Rosenberger LH, Hyslop T, Hwang ES, Plichta JK. Axillary Nodal Evaluation in Elderly Breast Cancer Patients: Potential Effects on Treatment Decisions and Survival. Annals of Surgical Oncology. PMID 29968029 DOI: 10.1245/S10434-018-6595-2 |
0.373 |
|
| 2018 |
Ong CT, Campbell BM, Thomas SM, Greenup RA, Plichta JK, Rosenberger LH, Force J, Hall A, Hyslop T, Hwang ES, Fayanju OM. Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database. Annals of Surgical Oncology. PMID 29855830 DOI: 10.1245/S10434-018-6533-3 |
0.395 |
|
| 2018 |
Freedman JA, Wang Y, Li X, Liu H, Moorman PG, George DJ, Lee NH, Hyslop T, Wei Q, Patierno SR. Single Nucleotide Polymorphisms of Stemness Genes Predicted to Regulate RNA Splicing, microRNA and Oncogenic Signaling are Associated with Prostate Cancer Survival. Carcinogenesis. PMID 29726910 DOI: 10.1093/Carcin/Bgy062 |
0.316 |
|
| 2018 |
Force J, Howie LJ, Abbott SE, Bentley R, Marcom PK, Kimmick G, Westbrook K, Sammons SL, Parks M, Topping DL, Emerson R, Broadwater G, Hyslop T, Blackwell KL, Nair SK. Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype. Clinical Breast Cancer. PMID 29615305 DOI: 10.1016/J.Clbc.2018.02.010 |
0.381 |
|
| 2018 |
Magbanua MJM, Rugo HS, Wolfe DM, Hauranieh L, Roy R, Pendyala P, Sosa E, Scott JH, Lee JS, Pitcher BN, Hyslop TM, Barry WT, Isakoff SJ, Dickler MN, Van't Veer LJ, et al. Expanded genomic profiling of circulating tumor cells in metastatic breast cancer patients to assess biomarker status and biology over time. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29311117 DOI: 10.1158/1078-0432.Ccr-17-2312 |
0.392 |
|
| 2018 |
Greenup RA, Rushing C, Fish L, Hyslop T, Peppercorn JM, Wheeler SB, Zafar Y, Myers E, Hwang ES. The costs of breast cancer care: Patient-reported experiences and preferences for transparency. Journal of Clinical Oncology. 36: 207-207. DOI: 10.1200/Jco.2018.36.30_Suppl.207 |
0.331 |
|
| 2018 |
Plichta JK, Thomas SM, Sergesketter AR, Fayanju OM, Greenup RA, Rosenberger LH, Kimmick GG, Hyslop T, Hwang ES. Restaging de novo metastatic breast cancer to refine prognostic estimates. Journal of Clinical Oncology. 36: e13083-e13083. DOI: 10.1200/Jco.2018.36.15_Suppl.E13083 |
0.392 |
|
| 2018 |
Force JM, Abbott S, Broadwater G, Stashko I, Westbrook KE, Kimmick GG, Sammons SL, Hyslop T, Brauer HA, Mashadi-Hossein A, Plichta JK, Hwang ES, Kauff ND, Weinhold KJ, Nair S, et al. Immune profiling of BRCA-mutated breast cancers. Journal of Clinical Oncology. 36: 585-585. DOI: 10.1200/Jco.2018.36.15_Suppl.585 |
0.359 |
|
| 2018 |
Oyekunle T, Thomas S, Greenup R, Hyslop T, Blackwell K. Abstract P6-10-01: Incidence and mortality among breast cancer patients < 40 years old: U.S. trends from 1992-2014 Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P6-10-01 |
0.343 |
|
| 2018 |
Ryser, Weaver D, Marks J, Hyslop T, Hwang E. Abstract P4-15-07: Quantifying the natural history and overtreatment rate of ductal carcinoma in situ Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P4-15-07 |
0.382 |
|
| 2018 |
Magbanua M, Hendrix L, Hyslop T, Barry W, Winer E, Hudis C, Toppmeyer D, Burnstein H, Qadir M, Ma C, Scott J, Park J, Rugo H. Abstract P2-01-01: Trajectory patterns of circulating tumor cells (CTC) in chemotherapy-treated metastatic breast cancer (MBC) patients predict poor clinical outcomes: CALGB 40502 (Alliance)/NCCTG N063H study Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P2-01-01 |
0.394 |
|
| 2018 |
Hwang E, Duong S, Bedrosian I, Allred J, Wisner D, Hyslop T, Caudle A, Guenther J, Hudis C, Winer E, Esserman L, Hylton N. Abstract GS5-05: Primary endocrine therapy for ER-positive ductal carcinoma in situ (DCIS) CALGB 40903 (Alliance) Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Gs5-05 |
0.348 |
|
| 2018 |
Zambeli-Ljepovic A, Wang F, Hyslop T, Roman SA, Sosa JA, Scheri RP. Total Thyroidectomy and Radioactive Iodine for Elderly Patients with Low-Risk Papillary Thyroid Cancer Confers No Survival Benefit over Lobectomy Alone Journal of the American College of Surgeons. 227: S88-S89. DOI: 10.1016/J.Jamcollsurg.2018.07.176 |
0.339 |
|
| 2017 |
Lane WO, Thomas SM, Blitzblau RC, Plichta JK, Rosenberger LH, Fayanju OM, Hyslop T, Hwang ES, Greenup RA. Surgical Resection of the Primary Tumor in Women With De Novo Stage IV Breast Cancer: Contemporary Practice Patterns and Survival Analysis. Annals of Surgery. PMID 29227346 DOI: 10.1097/Sla.0000000000002621 |
0.372 |
|
| 2017 |
Li P, Wuthrick E, Rappaport JA, Kraft C, Lin JE, Marszalowicz G, Snook AE, Zhan T, Hyslop TM, Waldman SA. GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome. Cancer Research. 77: 5095-5106. PMID 28916678 DOI: 10.1158/0008-5472.Can-17-0859 |
0.456 |
|
| 2017 |
Ong CT, Thomas SM, Blitzblau RC, Fayanju OM, Park TS, Plichta JK, Rosenberger LH, Hyslop T, Shelley Hwang E, Greenup RA. Patient Age and Tumor Subtype Predict the Extent of Axillary Surgery Among Breast Cancer Patients Eligible for the American College of Surgeons Oncology Group Trial Z0011. Annals of Surgical Oncology. PMID 28879416 DOI: 10.1245/S10434-017-6075-0 |
0.375 |
|
| 2017 |
Adam MA, Thomas S, Roman SA, Hyslop T, Sosa JA. Rethinking the Current American Joint Committee on Cancer TNM Staging System for Medullary Thyroid Cancer. Jama Surgery. PMID 28636692 DOI: 10.1001/Jamasurg.2017.1665 |
0.347 |
|
| 2017 |
Wang Y, Freedman JA, Liu H, Moorman PG, Hyslop T, George DJ, Lee NH, Patierno SR, Wei Q. Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer. International Journal of Cancer. PMID 28510291 DOI: 10.1002/Ijc.30787 |
0.312 |
|
| 2017 |
Chervoneva I, Freydin B, Hyslop T, Waldman SA. Modeling qRT-PCR dynamics with application to cancer biomarker quantification. Statistical Methods in Medical Research. 962280216683204. PMID 28504051 DOI: 10.1177/0962280216683204 |
0.579 |
|
| 2017 |
Cheng Q, Li X, Acharya CR, Hyslop T, Sosa JA. A novel integrative risk index of papillary thyroid cancer progression combining genomic alterations and clinical factors. Oncotarget. PMID 28187428 DOI: 10.18632/Oncotarget.15128 |
0.347 |
|
| 2017 |
Plichta JK, Thomas SM, Fayanju OM, Rosenberger LH, Park TS, Hyslop T, Greenup RA, Hwang ES. Temporal associations between prognostic indicators and overall survival after breast cancer. Journal of Clinical Oncology. 35: e18144-e18144. DOI: 10.1200/Jco.2017.35.15_Suppl.E18144 |
0.367 |
|
| 2017 |
Greenup RA, Thomas SM, Fayanju OM, Hyslop T, Hwang ES. Impact of insurance status on treatment for stage 0-IV breast cancer. Journal of Clinical Oncology. 35: 6532-6532. DOI: 10.1200/Jco.2017.35.15_Suppl.6532 |
0.39 |
|
| 2017 |
Ong CT, Thomas SM, Campbell BM, Greenup RA, Plichta JK, Rosenberger LH, Force JM, Hyslop T, Hwang ES, Fayanju OM. A population-based analysis of treatment and outcomes in 2,500 metaplastic breast cancer patients. Journal of Clinical Oncology. 35: 532-532. DOI: 10.1200/Jco.2017.35.15_Suppl.532 |
0.377 |
|
| 2017 |
Narloch J, Luedke C, Broadwater G, Priedigkeit N, Hall A, Hyslop T, Sammons SL, Huggins-Puhalla SL, Leone JP, Ramirez J, Kirkpatrick JP, Ewend MG, Fecci PE, Brufsky A, Lee AV, et al. Number of tumor-infiltrating lymphocytes in breast cancer brain metastases compared to matched breast primaries. Journal of Clinical Oncology. 35: 2049-2049. DOI: 10.1200/Jco.2017.35.15_Suppl.2049 |
0.373 |
|
| 2017 |
Campbell BM, Thomas SM, Ong CT, Greenup RA, Plichta JK, Rosenberger LH, Force JM, Hyslop T, Hwang ES, Fayanju OM. The epidemiology of metaplastic breast cancer: A review of 2,500 cases from the national cancer database. Journal of Clinical Oncology. 35: 1570-1570. DOI: 10.1200/Jco.2017.35.15_Suppl.1570 |
0.43 |
|
| 2017 |
Freedman J, Wang Y, Liu H, Moorman P, Hyslop T, George D, Lee N, Wei Q, Patierno S. Abstract B58: Single-nucleotide polymorphisms of race-related alternatively spliced genes associate with prostate cancer risk, aggressiveness and/or survival Cancer Epidemiology, Biomarkers & Prevention. 26. DOI: 10.1158/1538-7755.Disp16-B58 |
0.326 |
|
| 2017 |
Tanioka M, Fan C, Carey L, Hyslop T, Pitcher B, Parker J, Hoadley K, Henry N, Tolaney S, Dang C, Krop I, Harris L, Berry D, Mardis E, Perou C, et al. Abstract S3-05: Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-S3-05 |
0.383 |
|
| 2017 |
Hoadley K, Hyslop T, Fan C, Berry D, Hahn O, Tolaney S, Sikov W, Perou C, Carey L. Abstract PD1-03: Multivariate analysis of subtype and gene expression signatures predictive of pathologic complete response (pCR) in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance) Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-Pd1-03 |
0.392 |
|
| 2017 |
Narloch J, Harnden K, Broadwater G, Peterson B, Hyslop T, Kirkpatrick J, Fecci P, Kim G, Blackwell K. Abstract P5-08-12: HER2 status remains the primary predictor of improved survival in patients with BCBM over the past 2 decades (1996-2015) Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P5-08-12 |
0.399 |
|
| 2017 |
Force J, Abbott S, Broadwater G, Kimmick G, Westbrook K, Hwang S, Kauff N, Stashko I, Weinhold K, Nair S, Hyslop T, Blackwell K, Castellar E, Marcom P. Abstract P2-04-19: Elucidating the tumor immune microenvironment phenotype in early stage untreated BRCA mutated breast cancer patients Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P2-04-19 |
0.391 |
|
| 2016 |
Adam MA, Thomas S, Hyslop T, Scheri RP, Roman SA, Sosa JA. Exploring the Relationship Between Patient Age and Cancer-Specific Survival in Papillary Thyroid Cancer: Rethinking Current Staging Systems. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 4415-4420. PMID 27998233 DOI: 10.1200/Jco.2016.68.9372 |
0.31 |
|
| 2016 |
Greenup RA, Obeng-Gyasi S, Thomas S, Houck K, Lane WO, Blitzblau RC, Hyslop T, Hwang ES. The Effect of Hospital Volume on Breast Cancer Mortality. Annals of Surgery. PMID 27893532 DOI: 10.1097/Sla.0000000000002095 |
0.338 |
|
| 2016 |
Peck AR, Girondo MA, Liu C, Kovatich AJ, Hooke JA, Shriver CD, Hu H, Mitchell EP, Freydin B, Hyslop T, Chervoneva I, Rui H. Validation of tumor protein marker quantification by two independent automated immunofluorescence image analysis platforms. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 27312066 DOI: 10.1038/Modpathol.2016.112 |
0.558 |
|
| 2016 |
Lai Y, Wang C, Civan JM, Palazzo JP, Ye Z, Hyslop T, Lin J, Myers RE, Li B, Jiang B, Sama A, Xing J, Yang H. Effects of Cancer Stage and Treatment Differences on Racial Disparities in Survival from Colon Cancer: A United States Population-Based Study. Gastroenterology. PMID 26836586 DOI: 10.1053/J.Gastro.2016.01.030 |
0.371 |
|
| 2016 |
Palumbo A, Michael Y, Hyslop T. Latent class model characterization of neighborhood socioeconomic status. Cancer Causes & Control : Ccc. PMID 26797452 DOI: 10.1007/S10552-015-0711-4 |
0.356 |
|
| 2016 |
Lin JE, Colon-Gonzalez F, Blomain E, Kim GW, Aing A, Stoecker B, Rock J, Snook AE, Zhan T, Hyslop TM, Tomczak M, Blumberg RS, Waldman SA. Obesity-Induced Colorectal Cancer Is Driven by Caloric Silencing of the Guanylin-GUCY2C Paracrine Signaling Axis. Cancer Research. 76: 339-346. PMID 26773096 DOI: 10.1158/0008-5472.Can-15-1467-T |
0.481 |
|
| 2016 |
Hyslop T, Alvarado M, Forero A, Golshan M, Hieken T, Horton J, Hudis C, McGuire K, Meric-Bernstam F, Nanda R, Zagar T, Hwang S. Abstract S3-06: Treatment outcomes in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast MR imaging: Results of a secondary analysis of TBCRC 017 Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-S3-06 |
0.406 |
|
| 2015 |
Mu Z, Wang C, Ye Z, Austin L, Civan J, Hyslop T, Palazzo JP, Jaslow R, Li B, Myers RE, Jiang J, Xing J, Yang H, Cristofanilli M. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer. Breast Cancer Research and Treatment. PMID 26573830 DOI: 10.1007/S10549-015-3636-4 |
0.354 |
|
| 2015 |
Goodman CR, Sato T, Peck AR, Girondo MA, Yang N, Liu C, Yanac AF, Kovatich AJ, Hooke JA, Shriver CD, Mitchell EP, Hyslop T, Rui H. Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism. Oncogene. PMID 26096934 DOI: 10.1038/Onc.2015.193 |
0.4 |
|
| 2015 |
Adam MA, Pura J, Goffredo P, Dinan MA, Reed SD, Scheri RP, Hyslop T, Roman SA, Sosa JA. Presence and Number of Lymph Node Metastases Are Associated With Compromised Survival for Patients Younger Than Age 45 Years With Papillary Thyroid Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26077238 DOI: 10.1200/Jco.2014.59.8391 |
0.31 |
|
| 2015 |
Hegarty SE, Hyslop T, Dicker AP, Showalter TN. Radiation therapy after radical prostatectomy for prostate cancer: evaluation of complications and influence of radiation timing on outcomes in a large, population-based cohort. Plos One. 10: e0118430. PMID 25706657 DOI: 10.1371/Journal.Pone.0118430 |
0.301 |
|
| 2015 |
Wang C, Civan J, Lai Y, Cristofanilli M, Hyslop T, Palazzo JP, Myers RE, Li B, Ye Z, Zhang K, Xing J, Yang H. Racial disparity in breast cancer survival: the impact of pre-treatment hematologic variables. Cancer Causes & Control : Ccc. 26: 45-56. PMID 25359303 DOI: 10.1007/S10552-014-0481-4 |
0.361 |
|
| 2015 |
Adam MA, Pura J, Goffredo P, Dinan MA, Hyslop T, Reed SD, Scheri RP, Roman SA, Sosa JA. Impact of extent of surgery on survival for papillary thyroid cancer patients younger than 45 years. The Journal of Clinical Endocrinology and Metabolism. 100: 115-21. PMID 25337927 DOI: 10.1210/Jc.2014-3039 |
0.331 |
|
| 2015 |
Zhang K, Lai Y, Axelrod R, Campling B, Hyslop T, Civan J, Solomides C, Myers RE, Lu B, Bar Ad V, Li B, Ye Z, Yang H. Modeling the overall survival of patients with advanced-stage non-small cell lung cancer using data of routine laboratory tests. International Journal of Cancer. Journal International Du Cancer. 136: 382-91. PMID 24866905 DOI: 10.1002/Ijc.28995 |
0.341 |
|
| 2015 |
Snook A, Baybutt T, Mastrangelo M, Lewis N, Goldstein S, Kraft W, Oppong Y, Hyslop T, Myers R, Alexeev V, Eisenlohr L, Sato T, Waldman S. A Phase I study of Ad5-GUCY2C-PADRE in stage I and II colon cancer patients F1000research. 4. DOI: 10.7490/F1000Research.1111178.1 |
0.304 |
|
| 2015 |
Rui H, Sato T, Peck A, Girondo MA, Liu C, Kovatich AJ, Hooke JA, Shriver CD, Mitchell E, Hyslop T, Goodman C. Abstract P3-05-10: Glucocorticoid and aldosterone mimic progestin-induction of a therapy-resistant cytokeratin-5 positive cell population in estrogen receptor-positive breast cancer through a Bcl6-dependent mechanism Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-05-10 |
0.401 |
|
| 2015 |
Hyslop T, Li X, Duan R, Giuliano M, Giordano A, Orloff M, Rui H, Reuben JM, Cristofanilli M. Abstract 5295: Latent class longitudinal modeling of CTCs in ER+ metastatic breast cancer patients Cancer Research. 75: 5295-5295. DOI: 10.1158/1538-7445.Am2015-5295 |
0.387 |
|
| 2015 |
Blomain ES, Lin JE, Colón-González F, Kim GW, Hyslop T, Zhan T, Snook AE, Waldman SA. Abstract 2882: Calorie-induced silencing of the tumor suppressive guanylin-GUCY2C paracrine axis underlies colorectal cancer in obesity Cancer Research. 75: 2882-2882. DOI: 10.1158/1538-7445.Am2015-2882 |
0.523 |
|
| 2015 |
Lin J, Deng A, Hoffman-Censits J, Gibney G, Hyslop T, Miller B, Kilpatrick D, Jabbour S, Kevin Kelly W. An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients Cancer Treatment Communications. 4: 192-195. DOI: 10.1016/J.Ctrc.2015.11.003 |
0.325 |
|
| 2014 |
Wilson C, Lin JE, Li P, Snook AE, Gong J, Sato T, Liu C, Girondo MA, Rui H, Hyslop T, Waldman SA. The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 23: 2328-37. PMID 25304930 DOI: 10.1158/1055-9965.Epi-14-0440 |
0.364 |
|
| 2014 |
Lai Y, Palazzo JP, Cristofanilli M, Hyslop T, Civan J, Avery T, Myers RE, Li B, Ye Z, Xing J, Yang H. Erythropoiesis stimulating agents and clinical outcomes of invasive breast cancer patients receiving cytotoxic chemotherapy. Breast Cancer Research and Treatment. 148: 175-85. PMID 25261294 DOI: 10.1007/S10549-014-3152-Y |
0.419 |
|
| 2014 |
Sato T, Tran TH, Peck AR, Girondo MA, Liu C, Goodman CR, Neilson LM, Freydin B, Chervoneva I, Hyslop T, Kovatich AJ, Hooke JA, Shriver CD, Fuchs SY, Rui H. Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression. Oncogene. 33: 2215-24. PMID 23708665 DOI: 10.1038/Onc.2013.172 |
0.627 |
|
| 2014 |
Hoffman-Censits JH, Vaughn DJ, Lin J, Keefe SM, Haas NB, Kelly WK, Hyslop T, McGuire M, Robinson J, Khadar K, Nanda S, Kennedy B, Apolo AB. A phase II study of cabazitaxel in patients with urothelial carcinoma who have disease progression following platinum-based chemotherapy. Journal of Clinical Oncology. 32: e15519-e15519. DOI: 10.1200/Jco.2014.32.15_Suppl.E15519 |
0.324 |
|
| 2014 |
Rodriguez J, Limentani K, Andrel-Sendecki J, Hyslop T, Cristofanilli M, Jaslow RJ, Avery TP, Mitchell EP. Breast cancer in young women: A single center study. Journal of Clinical Oncology. 32: 595-595. DOI: 10.1200/Jco.2014.32.15_Suppl.595 |
0.368 |
|
| 2014 |
Palumbo A, Michael Y, Hyslop T. Abstract 4137: Latent class model characterization of neighborhood SES Cancer Research. 74: 4137-4137. DOI: 10.1158/1538-7445.Am2014-4137 |
0.396 |
|
| 2013 |
Yang N, Liu C, Peck AR, Girondo MA, Yanac AF, Tran TH, Utama FE, Tanaka T, Freydin B, Chervoneva I, Hyslop T, Kovatich AJ, Hooke JA, Shriver CD, Rui H. Prolactin-Stat5 signaling in breast cancer is potently disrupted by acidosis within the tumor microenvironment. Breast Cancer Research : Bcr. 15: R73. PMID 24004716 DOI: 10.1186/Bcr3467 |
0.624 |
|
| 2013 |
Wan S, Lai Y, Myers RE, Li B, Hyslop T, London J, Chatterjee D, Palazzo JP, Burkart AL, Zhang K, Xing J, Yang H. Preoperative platelet count associates with survival and distant metastasis in surgically resected colorectal cancer patients. Journal of Gastrointestinal Cancer. 44: 293-304. PMID 23549858 DOI: 10.1007/S12029-013-9491-9 |
0.325 |
|
| 2013 |
Hyslop T, Waldman SA. Molecular staging of node negative patients with colorectal cancer. Journal of Cancer. 4: 193-9. PMID 23459453 DOI: 10.7150/Jca.5830 |
0.374 |
|
| 2013 |
Hyslop T, Waldman SA. Guanylyl cyclase C as a biomarker in colorectal cancer. Biomarkers in Medicine. 7: 159-67. PMID 23387497 DOI: 10.2217/Bmm.12.90 |
0.392 |
|
| 2013 |
Hyslop T, Michael Y, Avery T, Rui H. Population and target considerations for triple-negative breast cancer clinical trials. Biomarkers in Medicine. 7: 11-21. PMID 23387481 DOI: 10.2217/Bmm.12.114 |
0.362 |
|
| 2013 |
Yamoah K, Beecham K, Hegarty SE, Hyslop T, Showalter T, Yarney J. Early results of prostate cancer radiation therapy: an analysis with emphasis on research strategies to improve treatment delivery and outcomes. Bmc Cancer. 13: 23. PMID 23324165 DOI: 10.1186/1471-2407-13-23 |
0.308 |
|
| 2013 |
Avery TP, Berger AC, Kovatich AJ, Rui H, Hyslop T, Mitchell EP. An adaptive randomized phase II trial to determine pathologic complete response with the addition of carboplatin with and without ABT-888 to standard chemotherapy in the neoadjuvant treatment of triple-negative breast cancer. Journal of Clinical Oncology. 31: TPS1135-TPS1135. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps1135 |
0.32 |
|
| 2013 |
Chen Y, Kovatich A, Fantacone-Campbell J, Hooke J, Kvecher L, Kovatich A, Gallagher C, Hueman M, Hyslop T, Mural R, Shriver C, Rui H, Hu H. Abstract P4-06-09: HER2+ and HER2- luminal B subtypes have similar overall survival and histologic grade distributions Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P4-06-09 |
0.35 |
|
| 2013 |
Kovatich A, Chen Y, Fantacone-Campbell J, Wareham J, Tafra L, Kvecher L, Hyslop T, Hooke J, Rui H, Shriver C, Mural R, Hu H. Abstract P4-06-03: Assays on core biopsies and surgically resected tumors may result in different subtyping of the invasive breast cancer from the same patient Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P4-06-03 |
0.353 |
|
| 2013 |
Girondo M, Peck A, Freydin B, Chervoneva I, Hyslop T, Kovatich A, Hooke J, Shriver C, Mitchell E, Rui H. Abstract P1-08-20: Increased risk of hormone therapy failure in breast cancers expressing low phospho-Stat5: Validation of quantitative immunofluorescence assay parameters Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P1-08-20 |
0.642 |
|
| 2012 |
Peck AR, Witkiewicz AK, Liu C, Klimowicz AC, Stringer GA, Pequignot E, Freydin B, Yang N, Ertel A, Tran TH, Girondo MA, Rosenberg AL, Hooke JA, Kovatich AJ, Shriver CD, ... ... Hyslop T, et al. Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes. Breast Cancer Research : Bcr. 14: R130. PMID 23036105 DOI: 10.1186/Bcr3328 |
0.398 |
|
| 2012 |
Champ CE, Hegarty SE, Shen X, Mishra MV, Dicker AP, Trabulsi EJ, Lallas CD, Gomella LG, Hyslop T, Showalter TN. Prognostic factors and outcomes after definitive treatment of female urethral cancer: a population-based analysis. Urology. 80: 374-81. PMID 22857759 DOI: 10.1016/J.Urology.2012.02.058 |
0.347 |
|
| 2012 |
Gong JP, Schulz S, Hyslop T, Waldman SA. GUCY2C molecular staging personalizes colorectal cancer patient management. Biomarkers in Medicine. 6: 339-48. PMID 22731908 DOI: 10.2217/Bmm.12.24 |
0.372 |
|
| 2012 |
Yang H, Qu F, Myers RE, Bao G, Hyslop T, Hu G, Fei F, Xing J. Genetic variations in stem cell-related genes and colorectal cancer prognosis. Journal of Gastrointestinal Cancer. 43: 584-93. PMID 22528324 DOI: 10.1007/S12029-012-9388-Z |
0.322 |
|
| 2012 |
Mejia A, Schulz S, Hyslop T, Weinberg DS, Waldman SA. Molecular staging individualizing cancer management. Journal of Surgical Oncology. 105: 468-74. PMID 22441898 DOI: 10.1002/Jso.21858 |
0.357 |
|
| 2012 |
Hyslop T, Weinberg DS, Schulz S, Barkun A, Waldman SA. Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer. Journal of Surgical Oncology. 106: 24-30. PMID 22252429 DOI: 10.1002/Jso.23051 |
0.34 |
|
| 2012 |
Shen X, Zaorsky NG, Mishra MV, Foley KA, Hyslop T, Hegarty S, Pizzi LT, Dicker AP, Showalter TN. Comparative effectiveness research for prostate cancer radiation therapy: current status and future directions. Future Oncology (London, England). 8: 37-54. PMID 22149034 DOI: 10.2217/Fon.11.131 |
0.318 |
|
| 2012 |
Hyslop T, Weinberg DS, Schulz S, Barkun A, Waldman SA. Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes. Cancer. 118: 2532-40. PMID 21887684 DOI: 10.1002/Cncr.26516 |
0.362 |
|
| 2012 |
Yamoah K, Beecham K, Hegarty S, Hyslop T, Showalter TN, Yarney J. Early results of prostate cancer radiation therapy at Korle Bu Teaching Hospital: An analysis with emphasis on research strategies to improve treatment delivery and outcomes among patients in Ghana. Journal of Clinical Oncology. 30: e15163-e15163. DOI: 10.1200/Jco.2012.30.15_Suppl.E15163 |
0.333 |
|
| 2011 |
Sullivan J, Gong Q, Hyslop T, Lavu H, Chipitsyna G, Yeo CJ, Arafat HA. Serum monocyte chemoattractant protein-1 in pancreatic cancer. Journal of Oncology. 2011: 518394. PMID 21977031 DOI: 10.1155/2011/518394 |
0.324 |
|
| 2011 |
Sato T, Neilson LM, Peck AR, Liu C, Tran TH, Witkiewicz A, Hyslop T, Nevalainen MT, Sauter G, Rui H. Signal transducer and activator of transcription-3 and breast cancer prognosis. American Journal of Cancer Research. 1: 347-55. PMID 21776434 |
0.31 |
|
| 2011 |
Witkiewicz AK, Rivadeneira DB, Ertel A, Kline J, Hyslop T, Schwartz GF, Fortina P, Knudsen ES. Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment. The American Journal of Pathology. 179: 1171-8. PMID 21756866 DOI: 10.1016/J.Ajpath.2011.05.043 |
0.382 |
|
| 2011 |
Peck AR, Witkiewicz AK, Liu C, Stringer GA, Klimowicz AC, Pequignot E, Freydin B, Tran TH, Yang N, Rosenberg AL, Hooke JA, Kovatich AJ, Nevalainen MT, Shriver CD, Hyslop T, et al. Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2448-58. PMID 21576635 DOI: 10.1200/Jco.2010.30.3552 |
0.377 |
|
| 2011 |
Xing J, Myers RE, He X, Qu F, Zhou F, Ma X, Hyslop T, Bao G, Wan S, Yang H, Chen Z. GWAS-identified colorectal cancer susceptibility locus associates with disease prognosis. European Journal of Cancer (Oxford, England : 1990). 47: 1699-707. PMID 21402474 DOI: 10.1016/J.Ejca.2011.02.004 |
0.357 |
|
| 2011 |
Hyslop T, Weinberg DS, Schulz S, Barkun A, Waldman SA. Occult tumor burden predicts disease recurrence in lymph node-negative colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3293-303. PMID 21307149 DOI: 10.1158/1078-0432.Ccr-10-3113 |
0.375 |
|
| 2011 |
Peck AR, Witkiewicz AK, Liu C, Stringer GA, Klimowicz AC, Pequignot E, Freydin B, Tran TH, Yang N, Rosenberg AL, Hooke JA, Kovatich AJ, Nevalainen MT, Shriver CD, Hyslop T, et al. Abstract 2277: Loss of nuclear localized and tyrosine phosphorylated Stat5: A predictor of poor clinical outcome and increased risk of antiestrogen therapy failure in breast cancer Cancer Research. 71: 2277-2277. DOI: 10.1158/1538-7445.Am2011-2277 |
0.408 |
|
| 2011 |
Peck A, Witkiewicz A, Liu C, Klimowicz A, Stringer G, Pequignot E, Freydin B, Yang N, Tran T, Rosenberg A, Hooke J, Kovatich A, Shriver C, Rimm D, Magliocco A, ... Hyslop T, et al. P1-06-24: Nuclear Localization of Stat5a Predicts Response to Antiestrogen Therapy and Prognosis of Clinical Breast Cancer Outcome. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P1-06-24 |
0.42 |
|
| 2010 |
Mejia A, Schulz S, Hyslop T, Weinberg DS, Waldman SA. Molecular staging estimates occult tumor burden in colorectal cancer. Advances in Clinical Chemistry. 52: 19-39. PMID 21275338 DOI: 10.1016/S0065-2423(10)52007-9 |
0.407 |
|
| 2010 |
Chervoneva I, Li Y, Schulz S, Croker S, Wilson C, Waldman SA, Hyslop T. Selection of optimal reference genes for normalization in quantitative RT-PCR. Bmc Bioinformatics. 11: 253. PMID 20470420 DOI: 10.1186/1471-2105-11-253 |
0.54 |
|
| 2010 |
Gu L, Vogiatzi P, Puhr M, Dagvadorj A, Lutz J, Ryder A, Addya S, Fortina P, Cooper C, Leiby B, Dasgupta A, Hyslop T, Bubendorf L, Alanen K, Mirtti T, et al. Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo. Endocrine-Related Cancer. 17: 481-93. PMID 20233708 DOI: 10.1677/Erc-09-0328 |
0.318 |
|
| 2010 |
Gu L, Dagvadorj A, Lutz J, Leiby B, Bonuccelli G, Lisanti MP, Addya S, Fortina P, Dasgupta A, Hyslop T, Bubendorf L, Nevalainen MT. Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth. The American Journal of Pathology. 176: 1959-72. PMID 20167868 DOI: 10.2353/Ajpath.2010.090653 |
0.315 |
|
| 2010 |
Hyslop T, Foley KA, Rui H, Mitchell E. Abstract A102: The role of socioeconomic status, pathology and genetic biomarkers in explaining racial disparities in breast cancer survival Cancer Epidemiology, Biomarkers & Prevention. 19. DOI: 10.1158/1055-9965.Disp-10-A102 |
0.422 |
|
| 2009 |
Mejia A, Schulz S, Hyslop T, Weinberg DS, Waldman SA. GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patients. Expert Review of Molecular Diagnostics. 9: 777-85. PMID 19895223 DOI: 10.1586/Erm.09.67 |
0.378 |
|
| 2009 |
Liu M, Casimiro MC, Wang C, Shirley LA, Jiao X, Katiyar S, Ju X, Li Z, Yu Z, Zhou J, Johnson M, Fortina P, Hyslop T, Windle JJ, Pestell RG. p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proceedings of the National Academy of Sciences of the United States of America. 106: 19035-9. PMID 19858489 DOI: 10.1073/Pnas.0910009106 |
0.337 |
|
| 2009 |
Showalter TN, Rao AS, Rani Anne P, Rosato FE, Rosato EL, Andrel J, Hyslop T, Xu X, Berger AC. Does intraoperative radiation therapy improve local tumor control in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma? A propensity score analysis. Annals of Surgical Oncology. 16: 2116-22. PMID 19437078 DOI: 10.1245/S10434-009-0498-1 |
0.306 |
|
| 2009 |
Waldman SA, Hyslop T, Schulz S, Barkun A, Nielsen K, Haaf J, Bonaccorso C, Li Y, Weinberg DS. Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. Jama. 301: 745-52. PMID 19224751 DOI: 10.1001/Jama.2009.141 |
0.334 |
|
| 2009 |
Jimbo M, Myers RE, Meyer B, Hyslop T, Cocroft J, Turner BJ, Weinberg DS. Reasons patients with a positive fecal occult blood test result do not undergo complete diagnostic evaluation. Annals of Family Medicine. 7: 11-6. PMID 19139444 DOI: 10.1370/Afm.906 |
0.309 |
|
| 2008 |
Witkiewicz A, Ryder A, Neilson LM, Utama FE, Tran TH, Hyslop T, Rui H. Transcription factors Stat5a and Stat5b: Favorable prognostic markers in breast cancer Journal of Clinical Oncology. 26: 22071-22071. DOI: 10.1200/Jco.2008.26.15_Suppl.22071 |
0.366 |
|
| 2008 |
Waldman SA, Hyslop T, Schulz S, Nielsen K, Haaf J, Bonaccorso C, Li Y, Barkun A, Weinberg D. A prospective multicenter study of guanylyl cyclase C (GCC), quantified by the reverse transcriptase-polymerase chain reaction (qRT-PCR), as a prognostic marker of occult metastases in lymph nodes of pN0 colorectal cancer patients Journal of Clinical Oncology. 26: 11011-11011. DOI: 10.1200/Jco.2008.26.15_Suppl.11011 |
0.329 |
|
| 2007 |
Chervoneva I, Li Y, Iglewicz B, Waldman S, Hyslop T. Relative quantification based on logistic models for individual polymerase chain reactions. Statistics in Medicine. 26: 5596-611. PMID 17968873 DOI: 10.1002/Sim.3127 |
0.721 |
|
| 2007 |
Calin GA, Liu CG, Ferracin M, Hyslop T, Spizzo R, Sevignani C, Fabbri M, Cimmino A, Lee EJ, Wojcik SE, Shimizu M, Tili E, Rossi S, Taccioli C, Pichiorri F, et al. Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell. 12: 215-29. PMID 17785203 DOI: 10.1016/J.Ccr.2007.07.027 |
0.303 |
|
| 2007 |
Li P, Schulz S, Bombonati A, Palazzo JP, Hyslop TM, Xu Y, Baran AA, Siracusa LD, Pitari GM, Waldman SA. Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology. 133: 599-607. PMID 17681179 DOI: 10.1053/j.gastro.2007.05.052 |
0.484 |
|
| 2007 |
Fortina P, Kricka LJ, Graves DJ, Park J, Hyslop T, Tam F, Halas N, Surrey S, Waldman SA. Applications of nanoparticles to diagnostics and therapeutics in colorectal cancer. Trends in Biotechnology. 25: 145-52. PMID 17316852 DOI: 10.1016/J.Tibtech.2007.02.005 |
0.339 |
|
| 2007 |
Chervoneva I, Hyslop T, Hauck WW. A multivariate test for population bioequivalence. Statistics in Medicine. 26: 1208-23. PMID 16810712 DOI: 10.1002/Sim.2605 |
0.536 |
|
| 2006 |
Waldman SA, Fortina P, Surrey S, Hyslop T, Kricka LJ, Graves DJ. Opportunities for near-infrared thermal ablation of colorectal metastases by guanylyl cyclase C-targeted gold nanoshells. Future Oncology (London, England). 2: 705-16. PMID 17155897 DOI: 10.2217/14796694.2.6.705 |
0.346 |
|
| 2006 |
Chervoneva I, Iglewicz B, Hyslop T. A general approach for two-stage analysis of multilevel clustered non-Gaussian data. Biometrics. 62: 752-9. PMID 16984317 DOI: 10.1111/J.1541-0420.2005.00512.X |
0.706 |
|
| 2006 |
Schulz S, Hyslop T, Haaf J, Bonaccorso C, Nielsen K, Witek ME, Birbe R, Palazzo J, Weinberg D, Waldman SA. A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4545-52. PMID 16899600 DOI: 10.1158/1078-0432.Ccr-06-0865 |
0.346 |
|
| 2006 |
Chervoneva I, Hyslop T, Iglewicz B, Johns L, Wolfe HR, Schulz S, Leong E, Waldman S. Statistical algorithm for assuring similar efficiency in standards and samples for absolute quantification by real-time reverse transcription polymerase chain reaction. Analytical Biochemistry. 348: 198-208. PMID 16336939 DOI: 10.1016/J.Ab.2005.10.042 |
0.715 |
|
| 2005 |
Tiro JA, Vernon SW, Hyslop T, Myers RE. Factorial validity and invariance of a survey measuring psychosocial correlates of colorectal cancer screening among African Americans and Caucasians. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 14: 2855-61. PMID 16365000 DOI: 10.1158/1055-9965.Epi-05-0217 |
0.346 |
|
| 2005 |
Witek ME, Nielsen K, Walters R, Hyslop T, Palazzo J, Schulz S, Waldman SA. The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8549-56. PMID 16361536 DOI: 10.1158/1078-0432.Ccr-05-1624 |
0.301 |
|
| 2005 |
Frick GS, Pitari GM, Weinberg DS, Hyslop T, Schulz S, Waldman SA. Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. Expert Review of Molecular Diagnostics. 5: 701-13. PMID 16149873 DOI: 10.1586/14737159.5.5.701 |
0.395 |
|
| 2004 |
Cornfield DB, Palazzo JP, Schwartz GF, Goonewardene SA, Kovatich AJ, Chervoneva I, Hyslop T, Schwarting R. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone. Cancer. 100: 2317-27. PMID 15160334 DOI: 10.1002/Cncr.20260 |
0.585 |
|
| 2003 |
Sifri R, Myers R, Hyslop T, Turner B, Cocroft J, Rothermel T, Grana J, Schlackman N. Use of cancer susceptibility testing among primary care physicians Clinical Genetics. 64: 355-360. PMID 12974741 DOI: 10.1034/J.1399-0004.2003.00131.X |
0.354 |
|
| 2003 |
Ober C, Aldrich CL, Chervoneva I, Billstrand C, Rahimov F, Gray HL, Hyslop T. Variation in the HLA-G promoter region influences miscarriage rates. American Journal of Human Genetics. 72: 1425-35. PMID 12721954 DOI: 10.1086/375501 |
0.526 |
|
| 2002 |
Berghella V, Haas S, Chervoneva I, Hyslop T. Patients with prior second-trimester loss: prophylactic cerclage or serial transvaginal sonograms? American Journal of Obstetrics and Gynecology. 187: 747-51. PMID 12237658 DOI: 10.1067/Mob.2002.124289 |
0.534 |
|
| 2000 |
Myers RE, Hyslop T, Wolf TA, Burgh D, Kunkel EJS, Oyesanmi OA, Chodak GJ. African-American men and intention to adhere to recommended follow-up for an abnormal prostate cancer early detection examination result Urology. 55: 716-720. PMID 10792087 DOI: 10.1016/S0090-4295(99)00588-9 |
0.309 |
|
| Show low-probability matches. |